FIELD: medicine.
SUBSTANCE: present invention relates to the field of medicine, namely to a pharmaceutical composition in solid dosage form containing: (a) from 1 mg to 60 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl-4-(2 -(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate or a pharmaceutically acceptable salt thereof; (b) 50 mg to 175 mg microcrystalline cellulose; (c) 6 mg to 15 mg croscarmellose sodium; and (d) 0.5 mg to about 2.5 mg magnesium stearate.
EFFECT: invention provides for the creation of a stable pharmaceutical composition.
7 cl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
CRYSTALLINE FORMS OF MAGL INHIBITOR | 2017 |
|
RU2799564C2 |
MAGL INHIBITORS | 2017 |
|
RU2754536C1 |
SPIROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2781639C2 |
HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | 2018 |
|
RU2726631C1 |
PYRAZOLE-BASED MAGL INHIBITORS | 2018 |
|
RU2789157C2 |
NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES | 2005 |
|
RU2389718C2 |
SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | 2011 |
|
RU2603637C2 |
COMPOUNDS WITH CONDENSED RINGS | 2019 |
|
RU2783414C2 |
COMPOUNDS OF TETRAHYDROPYRASOLOPIRIMIDINE | 2013 |
|
RU2677291C2 |
PYRROLIDINE AND PIPERIDINE COMPOUNDS | 2020 |
|
RU2803455C1 |
Authors
Dates
2022-06-28—Published
2017-11-15—Filed